Colorado

Colorado’s programme developed in stages: voter approval in 2022, statutory build-out in 2023 through SB 23-290, implementation refinements in 2024 through SB 24-198, and local licensing overlays such as Denver’s 2025 ordinance. SB 24-198 was especially important because it formally authorised facilitator education programmes under DORA, updated testing and destruction rules, and clarified certain facility and transfer provisions.###

The next policy frontier is expansion beyond psilocybin/psilocin. Proposition 122 and SB 23-290 contemplate future inclusion of DMT, ibogaine and mescaline after 1 Jun 2026 if recommended and approved through the state process. As of 15 May 2026, that expansion has not yet taken effect and should not be treated as live regulated access.###

HB 26-1325 is the main current watchpoint. As of mid-May 2026 it had passed the General Assembly and would establish an ibogaine research pilot programme in the Behavioural Health Administration, contingent on federal approval, while also making changes to licensing priority and rulemaking authority. Because it had not yet become law by 15 May 2026, it should be labelled passed/pending enactment rather than enacted.###

Colorado’s research profile is increasingly connected to, but not defined by, its policy framework. The University of Colorado Anschutz hosts a Psychedelic Research Consortium, and ClinicalTrials.gov results show Colorado-based interventional work including a University of Colorado Anschutz trial of psilocybin for treatment-resistant depression and Denver sites in multicentre major depressive disorder studies.###

That matters because Colorado is not only a services-regulation story. It is also becoming a site for conventional sponsor-led drug development and academic investigation, including university-led work at Anschutz and commercial trial-site activity in Denver. However, the state-regulated natural-medicine system and FDA-pathway clinical trials remain legally distinct and should not be conflated.###

Colorado also continues to serve as a national convening location. MAPS announced and then held Psychedelic Science 2025 in Denver, reinforcing Colorado’s visibility for researchers, policy professionals, funders and conference partners even though conference activity is not itself evidence of treatment access or scientific output.###

Colorado’s implementation machinery is unusually developed. DOR licenses businesses such as healing centres, cultivations, manufacturers and testing facilities, while DORA licenses facilitators. DOR’s homepage says current natural-medicine rules took effect on 1 Oct 2024, and the Colorado Register listed a further Natural Medicine Division rules hearing for 22 Apr 2026.###

DORA’s public materials also give unusually concrete operational detail. Approved facilitator training programmes must offer at least 150 hours across topics including ethics, trauma-informed care, suicide risk, screening, preparation, administration, integration and group facilitation; clinical facilitator applicants must already hold one of several named Colorado clinical licences and complete approved training, practicum and consultation. Session-form libraries include required disclosures, de-identified data opt-out forms, health-history screening, informed consent, supportive-touch consent, transport planning and adverse-reaction reporting.###

The programme is operational but still moving. DORA’s monthly application data and training-programme list, and DOR’s business application counts, show real uptake but also continuing administrative churn. For anyone publishing counts, those numbers should be re-checked immediately before publication because they are dynamic.###

Colorado’s ecosystem now includes policy, training, business and research layers with verified physical presence. DORA’s approved training-programme list includes Colorado-based programmes such as Bodhi Academy in Boulder, the Center for Medicinal Mindfulness in Boulder, and Ceremonia in Arvada. Those are concrete ecosystem actors tied directly to the state’s implementation framework.###

Denver is also a practical ecosystem hub. The city built a natural-medicine workgroup in 2024, adopted a local natural-medicine code in 2025, and requires a local healing-centre licence. Combined with Psychedelic Science 2025 in Denver and the CU Anschutz research presence, Colorado offers a rare combination of operational services infrastructure and visible professional convening.###

For investors and partners, the key distinction is that Colorado has a state-regulated non-FDA natural-medicine services market, but it is not the same thing as a reimbursed medical treatment market. For clinicians and patient-access researchers, the state now provides a lawful facilitated-access route, yet one shaped by licensure, local overlays, training requirements, disclosure rules and likely self-pay economics.###

Over the next 12 to 24 months, Colorado is likely to remain the most important US test case for non-FDA state-regulated psychedelic access. Immediate watchpoints include whether additional natural medicines are formally added to the regulated programme after 1 Jun 2026, whether HB 26-1325 becomes law, and how fast local jurisdictions adopt or tighten local licensing overlays.###

Actual patient access should broaden as more licensed healing centres and facilitators come online, but the main constraints are likely to be cost, geographic distribution, local compliance burdens and the still-young training pipeline. There is still no verified reimbursement pathway for natural-medicine services in the primary sources reviewed here, so access growth is likely to be operational rather than payer-driven in the near term.###